Safety of approved MR contrast media for intravenous injection

Journal of Magnetic Resonance Imaging

Volumn 12, Issue 2, 2000, Pages 205-213

  Runge, Val M ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

Contrast agents; Contrast media; Gadolinium; Magnetic resonance; Toxicity

Indexed keywords

CONTRAST MEDIUM; GADODIAMIDE; GADOLINIUM CHELATE; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE; GADOTERIC ACID; GADOTERIDOL; MANGAFODIPIR; SUPERPARAMAGNETIC IRON OXIDE;

ANAPHYLAXIS; ARTICLE; CLINICAL PRACTICE; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DRUG SAFETY; HUMAN; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OSMOLALITY; PRIORITY JOURNAL; URTICARIA;

ANAPHYLAXIS; CHELATING AGENTS; CONTRAST MEDIA; EDETIC ACID; GADOLINIUM; HUMANS; INJECTIONS, INTRAVENOUS; IRON; MAGNETIC RESONANCE IMAGING; MOLECULAR STRUCTURE; OXIDES; PYRIDOXAL PHOSPHATE; SAFETY;

EID: 0033852026     PISSN: 10531807     EISSN: None     Source Type: Journal    
DOI: 10.1002/1522-2586(200008)12:2<205::AID-JMRI1>3.0.CO;2-P     Document Type: Article

References (88)

1. Vogl TJ, Pegios W, McMahon C, et al. Gadobenate dimeglumine - a new contrast agent for MR imaging: preliminary evaluation in healthy volunteers. AJR 1992;158:887-892.
2. Spinazzi A, Lorusso V, Pirovano G, Kirchin M. Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. Acad Radiol 1999;6:282-291.
3. Staks T, Schuhmann-Giampieri G, Frenzel T, et al. Pharmacokinetics, dose proportionality, and tolerability of gadobutrol after single intravenous injection in healthy volunteers. Invest Radiol 1994;29: 709-715.
4. Hartmann M, Forsting M, Jansen O, et al. [Does the administration of a high dose of a paramagnetic contrast medium (Gadovist) improve the diagnostic value of magnetic resonance tomography in glioblastomas?]. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1996;164:119-125.
5. Small WC, DeSimone-Macchi D, Parker JR, et al. A multisite phase III study of the safety and efficacy of a new manganese chloride-based gastrointestinal contrast agent for MRI of the abdomen and pelvis. J Magn Reson Imaging 1999;10:15-24.
6. Hamm B, Staks T, Muhler A, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 1995;195:785-792.
7. Reimer P, Rummeny EJ, Shamsi K, et al. Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. Radiology 1996;199:177-183.
8. Giovagnoni A, Paci E. Liver. III: Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg). Magn Reson Imaging Clin North Am 1996;4:61-72.
9. Ni Y, Marchal G. Enhanced magnetic resonance imaging for tissue characterization of liver abnormalities with hepatobiliary contrast agents: an overview of preclinical animal experiments. Top Magn Reson Imaging 1998;9:183-195.
10. Hamm B, Staks T, Taupitz M, et al. Contrast-enhanced MR imaging of liver and spleen: first experience in humans with a new super-paramagnetic iron oxide. J Magn Reson Imaging 1994;4:659-668.
11. Laniado M, Kopp AF. [Current status of the clinical development of MR contrast media]. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1997;167:541-550.
12. Chen F, Ward J, Robinson PJ. MR imaging of the liver and spleen: a comparison of the effects on signal intensity of two superparamagnetic iron oxide agents. Magn Reson Imaging 1999;17:549-556.
13. Runge VM, Schoerner W, Niendorf HP, et al. Initial clinical evaluation of gadolinium DTPA for contrast-enhanced magnetic resonance imaging. Magn Reson Imaging 1985;3:27-35.
14. Goldstein HA, Kashanian FK, Blumetti RF, et al. Safety assessment of gadopentetate dimeglumine in U.S. clinical trials. Radiology 1990;174:17-23.
15. Nelson KL, Gifford LM, Lauber-Huber C, et al. Clinical safety of gadopentetate dimeglumine. Radiology 1995;196:439-443.
16. Niendorf HP., Alhassan A, Geens VR, Clauss W. Safety review of gadopentetate dimeglumine. Extended clinical experience after more than five million applications. Invest Radiol 1994;29(suppl 2):S179-182.
17. Runge VM, Bradley WG, Brant-Zawadzki MN, et al. Clinical safety and efficacy of gadoteridol: a study in 411 patients with suspected intracranial and spinal disease. Radiology 1991;181:701-709.
18. Seiderer M. Phase III clinical studies with gadoteridol for the evaluation of neurologic pathology. A European perspective. Invest Radiol 1992;27(suppl 1):S33-38.
19. Olukotun AY, Parker JR, Meeks MJ, et al. Safety of gadoteridol injection: U.S. clinical trial experience. J Magn Reson Imaging 1995;5:17-25.
20. Yuh WT, Fisher DJ, Runge VM, et al. Phase III multicenter trial of high-dose gadoteridol in MR evaluation of brain metastases. AJNR 1994;15:1037-1051.
21. Runge VM, Parker JR. Worldwide clinical safety assessment of gadoteridol injection: an update. Eur Radiol 1997;7(suppl 5):243-245.
22. Tweedle MF. The ProHance story: the making of a novel MRI contrast agent. Eur Radiol 1997;7(suppl 5):225-230.
23. Sze G, Brant-Zawadzki M, Haughton VM, et al. Multicenter study of gadodiamide injection as a contrast agent in MR imaging of the brain and spine. Radiology 1991;181:693-699.
24. Brugieres P, Gaston A, Degryse HR, et al. Randomised double blind trial of the safety and efficacy of two gadolinium complexes (Gd-DTPA and Gd-DOTA). Neuroradiology 1994;36:27-30.
25. Oudkerk M, Sijens PE, Van Beek EJ, Kuijpers TJ. Safety and efficacy of Dotarem (Gd-DOTA) versus Magnevist (Gd-DTPA) in magnetic resonance imaging of the central nervous system. Invest Radiol 1995;30:75-78.
26. Tweedle MF. Nonionic or neutral? Radiology 1991;178:891.
27. McAlister WH, McAlister VI, Kissane JM. The effect of Gd-dimeglumine on subcutaneous tissues: a study with rats. AJNR 1990;11: 325-327.
28. Cohan RH, Leder RA, Herzberg AJ, et al. Extravascular toxicity of two magnetic resonance contrast agents. Preliminary experience in the rat. Invest Radiol 1991;26:224-226.
29. Vehmas T, Markkola AT. Gd-DTPA as an alternative contrast agent in conventional and interventional radiology. Acta Radiol 1998;39: 223-226.
30. Tweedle MF, Hagan JJ, Kumar K, et al. Reaction of gadolinium chelates with endogenously available ions. Magn Reson Imaging 1991;9:409-415.
31. Puttagunta NR, Gibby WA, Puttagunta VL. Comparative transmetallation kinetics and thermodynamic stability of gadolinium-DTPA bis-glucosamide and other magnetic resonance imaging contrast media. Invest Radiol 1996;31:619-624.
32. Wedeking P, Kumar K, Tweedle MF. Dissociation of gadolinium chelates in mice: relationship to chemical characteristics. Magn Reson Imaging 1992;10:641-648.
33. Tweedle MF, Wedeking P, Kumar K. Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. Invest Radiol 1995;30:372-380.
34. Puttagunta NR, Gibby WA, Smith GT. Human in vivo comparative study of zinc and copper transmetallation after administration of magnetic resonance imaging contrast agents. Invest Radiol 1996; 31:739-742.
35. Corot C, Idee JM, Hentsch AM, et al. Structure-activity relationship of macrocyclic and linear gadolinium chelates: investigation of transmetallation effect on the zinc-dependent metallopeptidase angiotensin-converting enzyme. J Magn Reson Imaging 1998;8:695-702.
36. Toft KG, Hustvedt SO, Grant D, et al. Metabolism and pharmacokinetics of MnDPDP in man. Acta Radiol 1997;38:677-689.
37. Toft KG, Kindberg GM, Skotland T. Mangafodipir trisodium injection, a new contrast medium for magnetic resonance imaging: in vitro metabolism and protein binding studies of the active component MnDPDP in human blood. J Pharm Biomed Anal 1997;15: 983-988.
38. Toft KG, Hustvedt SO, Grant D, et al. Metabolism of mangafodipir trisodium (MnDPDP), a new contrast medium for magnetic resonance imaging, in beagle dogs. Eur J Drug Metab Pharmacokinet 1997;22:65-72.
39. Weiss KL. Severe anaphylactoid reaction after i.v. Gd-DTPA. Magn Reson Imaging 1990;8:817-818.
40. Lufkin RB. Severe anaphylactoid reaction to Gd-DTPA. Radiology 1990;176:879.
41. Tishler S, Hoffman JC, Jr. Anaphylactoid reactions to i.v. gadopentetate dimeglumine. AJNR 1990;11:1167.
42. Salonen OL. Case of anaphylaxls and four cases of allergic reaction following Gd-DTPA administration. J Comput Assist Tomogr 1990; 14:912-913.
43. Tardy B, Guy C, Barral G, et al. Anaphylactic shock induced by intravenous gadopentetate dimeglumine. Lancet 1992;339(8791): 494.
44. Katoh A, Kishikawa T, Kudo S, et al. [Anaphylactoid reaction after intravenous administration of Gd-DTPA]. Nippon Igaku Hoshasen Gakkai Zasshi 1993;53:973-975.
45. Nomura M, Takeshita G, Katada K, et al. [A case of anaphylactic shock following the administration of Gd-DTPA]. Nippon Igaku Hoshasen Gakkai Zasshi 1993;53:1387-1391.
46. Jordan RM, Mintz RD. Fatal reaction to gadopentetate dimeglumine. Am J Roentgenol 1995;164:743-744.
47. Shellock FG, Hahn HP, Mink JH, Itskovich E. Adverse reaction to intravenous gadoteridol. Radiology 1993;189:151-152.
48. Witte RJ, Anzai LL. Life-threatening anaphylactoid reaction after intravenous gadoteridol administration in a patient who had previously received gadopentetate dimeglumine. AJNR 1994;15:523-524.
49. Meuli RA, Maeder P. Life-threatening anaphylactoid reaction after iv injection of gadoterate meglumine. AJR 1996;166:729.
50. Carr JJ. Magnetic resonance contrast agents for neuroimaging. Safety issues. Neuroimaging Clin North Am 1994;4:43-54.
51. Niendorf HP, Dinger JC, Haustein J, et al. Tolerance data of Gd-DTPA: a review. Eur J Radiol 1991;13:15-20.
52. Murphy KJ, Brunberg JA, Cohan RH. Adverse reactions to gadolinium contrast media: a review of 36 cases. AJR 1996;167:847-849.
53. Caro JJ, Trindade E, McGregor M. The cost-effectiveness of replacing high-osmolality with low-osmolality contrast media. AJR 1992; 159:869-874.
54. Hustvedt SO, Grant D, Southon TE, Zech K. Plasma pharmacokinetics, tissue distribution and excretion of MnDPDP in the rat and dog after intravenous administration. Acta Radiol 1997;38:690-699.
55. Lim KO, Stark DD, Leese FT, et al. Hepatobiliary MR imaging: first human experience with MnDPDP. Radiology 1991;178:79-82.
56. Kopp AF, Laniado M, Aicher KP, et al. [Manganese DPDP as a contrast medium for MR tomography of focal liver lesions. Tolerance and image quality in 20 patients]. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1992;157:539-547.
57. Rummeny E, Ehrenheim C, Gehl HB, et al. Manganese-DPDP as a hepatobiliary contrast agent in the magnetic resonance imaging of liver tumors. Results of clinical phase II trials in Germany including 141 patients. Invest Radiol 1991;26(suppl 1):S142-145.
58. Aicher KP, Laniado M, Kopp AF, et al. Mn-DPDP-enhanced MR imaging of malignant liver lesions: efficacy and safety in 20 patients. J Magn Reson Imaging 1993;3:731-737.
59. Toft KG, Friisk GA, Skotland T. Mangafodipir trisodium injection, a new contrast medium for magnetic resonance imaging: detection and quantitation of the parent compound MnDPDP and metabolites in human plasma by high performance liquid chromatography. J Pharm Biomed Anal 1997;15:973-981.
60. Wang C, Ahlstrom H, Ekholm S, et al. Diagnostic efficacy of MnDPDP in MR imaging of the liver. A phase III multicentre study. Acta Radiol 1997;38:643-649.
61. Torres CG, Lundby B, Sterud AT, et al. MnDPDP for MR imaging of the liver. Results from the European phase III studies. Acta Radiol 1997;38:631-637.
62. Mayo-Smith WW, Schima W, Saini S, et al. Pancreatic enhancement and pulse sequence analysis using low-dose mangafodipir trisodium. AJR 1998;170:649-652.
63. Wang C, Johansson L, Western A, et al. Sequence optimization in mangafodipir trisodium-enhanced liver and pancreas MRI. J Magn Reson Imaging 1999;9:280-284.
64. Ni Y, Petre C, Bosmans H, et al. Comparison of manganese biodistribution and MR contrast enhancement in rats after intravenous injection of MnDPDP and MnC12. Acta Radiol 1997;38:700-707.
65. Schima W, Petersein J, Hahn PF, et al. Contrast-enhanced MR imaging of the liver: comparison between Gd-BOPTA and Mangafodipir. J Magn Reson Imaging 1997;7:130-135.
66. Laniado M, Chachuat A. [The Endorem tolerance profile]. Radiologe 1995;35(suppl 2):S266-270.
67. Stark DD, Weissleder R, Elizondo G, et al. Superparamagnetic iron oxide: clinical application as a contrast agent for MR imaging of the liver. Radiology 1988;168:297-301.
68. Yoshikawa K, Sasaki Y. Ogawa N. Sakuma S. [Clinical application of AMI-25 (superparamagnetic iron oxide) for the MR imaging of hepatic tumors: a multicenter clinical phase III study]. Nippon Igaku Hoshasen Gakkai Zasshi 1994;54:137-153.
69. Ros PR, Freeny PC, Harms SE, et al. Hepatic MR imaging with ferumoxides: a multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions. Radiology 1995;196:481-488.
70. Ferrucci JT, Stark DD. Iron oxide-enhanced MR imaging of the liver and spleen: review of the first 5 years. AJR 1990;155:943-950.
71. Rofsky NM, Weinreb JC, Bosniak MA, et al. Renal lesion characterization with gadolinium-enhanced MR imaging: efficacy and safety in patients with renal insufficiency. Radiology 1991;180: 85-89.
72. Rominger MB, Kenney PJ, Morgan DE, et al. Gadolinium-enhanced MR imaging of renal masses. Radiographics 1992;12:1097-1116.
73. Terens WL, Gluck R, Golimbu M. Rofsky NM. Use of gadolinium-DTPA-enhanced MRI to characterize renal mass in patient with renal insufficiency. Urology 1992;40:152-154.
74. Brown ED, Semelka RC. Magnetic resonance imaging of the adrenal gland and kidney. Top Magn Reson Imaging 1995;7:90-101.
75. Yamashita Y, Miyazaki T, Hatanaka Y, Takahashi M. Dynamic MRI of small renal cell carcinoma. J Comput Assist Tomogr 1995;19: 759-765.
76. Kaufman JA, Geller SC, Waltman AC. Renal insufficiency: gadopentetate dimeglumine as a radiographic contrast agent during peripheral vascular interventional procedures. Radiology 1996;198:579-581.
77. Ghantous VE, Eisen TD, Sherman AH, Finkelstein OF. Evaluating patients with renal failure for renal artery stenosis with gadolinium-enhanced magnetic resonance angiography. Am J Kidney Dis 1999;33:36-42.
78. Cambria RP, Kaufman JL, Brewster DC, et al. Surgical renal artery reconstruction without contrast arteriography: the role of clinical profiling and magnetic resonance angiography. J Vase Surg 1999; 29:1012-1021.
79. Schuhmann-Giampieri G, Krestin G. Pharmacokinetics of Gd-DTPA in patients with chronic renal failure. Invest Radiol 1991;26: 975-979.
80. Haustein J, Niendorf HP, Krestin G, et al. Renal tolerance of gadolinium-DTPA/dimeglumine in patients with chronic renal failure. Invest Radiol 1992;27:153-156.
81. Bellin MF, Deray G, Assogba U, et al. Gd-DOTA: evaluation of its renal tolerance in patients with chronic renal failure. Magn Reson Imaging 1992;10:115-118.
82. Dorsam J, Knopp MV, Schad L, et al. Elimination of gadolinium-DTPA by peritoneal dialysis. Nephrol Dial Transplant 1995;10: 1228-1230.
83. Choyke PL, Girton ME, Vaughan EM, et al. Clearance of gadolinium chelates by hemodialysis: an in vitro study. J Magn Reson Imaging 1995;5:470-472.
84. Niendorf ER, Santyr GE, Brazy PC, Grist TM. Measurement of Gd-DTPA dialysis clearance rates by using a look-locker imaging technique. Magn Reson Med 1996;36:571-578.
85. Arsenault TM, King BF, Marsh JW, Jr., et al. Systemic gadolinium toxicity in patients with renal insufficiency and renal failure: retrospective analysis of an initial experience. Mayo Clin Proc 1996; 71:1150-1154.
86. Yoshikawa K, Davies A. Safety of ProHance in special populations. Eur Radiol 1997;7(suppl 5):246-250.
87. Joffe P, Thomsen HS, Meusel M. Pharmaeokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 1998;5:491-502.
88. Hammer FD, Goffette PP, Malaise J, Mathurin P. Gadolinium dimeglumine: an alternative contrast agent for digital subtraction angiography. Eur Radiol 1999;9:128-136.